Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Reaches New 1-Year High - Still a Buy?

Key Points

• Kiniksa Pharmaceuticals International (NASDAQ:KNSA) reached a new 52-week high of $39.25, with recent trading activity showing increased investor interest.
• Wall Street analysts have provided positive ratings, with several firms raising price targets, including Jefferies Financial Group's increase to $54.00 and a new coverage by TD Cowen with a $60.00 target.
• Insider trading activity has seen significant stock sales, with director Thomas Malley and COO Eben Tessari reducing their stakes, indicating a possible shift in confidence among executives.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report)'s share price reached a new 52-week high during mid-day trading on Thursday . The company traded as high as $39.25 and last traded at $39.20, with a volume of 46431 shares changing hands. The stock had previously closed at $38.31.

Wall Street Analysts Forecast Growth

KNSA has been the topic of a number of recent research reports. Jefferies Financial Group increased their price objective on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a research report on Tuesday, July 29th. Wells Fargo & Company increased their price objective on Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the company an "overweight" rating in a research report on Thursday, September 25th. Weiss Ratings reiterated a "hold (c)" rating on shares of Kiniksa Pharmaceuticals International in a research report on Wednesday. Zacks Research lowered Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "hold" rating in a research report on Monday. Finally, TD Cowen began coverage on Kiniksa Pharmaceuticals International in a research report on Monday, September 29th. They issued a "buy" rating and a $60.00 price target on the stock. Seven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, Kiniksa Pharmaceuticals International has an average rating of "Moderate Buy" and a consensus price target of $44.29.

Kiniksa Pharmaceuticals International Stock Performance

The firm has a market capitalization of $2.82 billion, a P/E ratio of 952.99 and a beta of 0.16. The company has a 50-day moving average price of $35.03 and a 200-day moving average price of $28.97.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings data on Tuesday, July 29th. The company reported $0.23 EPS for the quarter, topping the consensus estimate of $0.18 by $0.05. The business had revenue of $156.80 million for the quarter, compared to the consensus estimate of $145.21 million. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. Equities analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current year.

Insiders Place Their Bets

In related news, Director Thomas Malley sold 78,233 shares of the firm's stock in a transaction on Thursday, August 14th. The stock was sold at an average price of $33.09, for a total transaction of $2,588,729.97. Following the sale, the director owned 12,546 shares of the company's stock, valued at approximately $415,147.14. This trade represents a 86.18% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Eben Tessari sold 42,000 shares of the firm's stock in a transaction on Monday, September 29th. The stock was sold at an average price of $38.33, for a total value of $1,609,860.00. Following the sale, the chief operating officer directly owned 34,552 shares in the company, valued at $1,324,378.16. The trade was a 54.86% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 603,371 shares of company stock worth $20,434,869. 53.48% of the stock is owned by corporate insiders.

Institutional Trading of Kiniksa Pharmaceuticals International

Several hedge funds and other institutional investors have recently modified their holdings of the company. Rubric Capital Management LP raised its stake in shares of Kiniksa Pharmaceuticals International by 15.6% in the 2nd quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company's stock valued at $108,184,000 after purchasing an additional 526,567 shares during the period. Vanguard Group Inc. raised its stake in shares of Kiniksa Pharmaceuticals International by 4.7% in the 1st quarter. Vanguard Group Inc. now owns 3,359,101 shares of the company's stock valued at $74,606,000 after purchasing an additional 151,604 shares during the period. Acadian Asset Management LLC raised its stake in shares of Kiniksa Pharmaceuticals International by 22.6% in the 2nd quarter. Acadian Asset Management LLC now owns 1,267,989 shares of the company's stock valued at $35,067,000 after purchasing an additional 233,668 shares during the period. Qube Research & Technologies Ltd raised its stake in shares of Kiniksa Pharmaceuticals International by 277.8% in the 2nd quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company's stock valued at $24,581,000 after purchasing an additional 653,236 shares during the period. Finally, Millennium Management LLC raised its stake in shares of Kiniksa Pharmaceuticals International by 8.7% in the 1st quarter. Millennium Management LLC now owns 847,124 shares of the company's stock valued at $18,815,000 after purchasing an additional 67,452 shares during the period. Institutional investors and hedge funds own 53.95% of the company's stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.